Comparison of bone marrow tissue- and adipose tissue-derived mesenchymal stem cells in the treatment of sepsis in a murine model of lipopolysaccharide-induced sepsis.
Mesenchymal stem cells (MSCs) have been reported to regulate the systemic inflammatory response and sepsis-induced immunologic injury pre-clinically. However, whether MSCs from different sources elicit identical effects remains to be elucidated. The present study compared the effect of bone marrow‑derived MSCs (BMSCs) and adipose tissue-derived MSCs (ADMSCs) in a murine model of lipopolysaccharide (LPS)‑induced sepsis. SPF BALB/c mice were induced with an injection of LPS (10 mg/kg; 1 mg/ml) via the tail vein. To compare the effect of MSCs on the septic mice, either saline, BMSCs or ADMSCs were injected via the tail vein 5 min following the administration of LPS. The survival rates and body temperatures of the mice were observed regularly up to 48 h. The serum levels of pro‑inflammatory cytokines, including tumour necrosis factor‑α, interleukin (IL)‑6 and IL‑8, anti‑inflammatory cytokines, including IL‑2, IL‑4 and IL‑10, and biochemical markers, including lactate, creatinine, alanine aminotransferase and aspertate aminotransferase, were analyzed at 6 h. The BMSCs and ADMSCs significantly reduced mortality rates, body‑temperature fluctuations, serum levels of biochemical markers and the majority of cytokines. However, the levels of IL‑8 in the BMSC and ADMSC groups were increased and decreased, respectively. These findings suggested that BMSCs and ADMSCs ameliorated sepsis-associated organ injury and mortality, and had a similar regulatory effect on pro‑ and anti‑inflammatory cytokines despite the different MSC sources. Therefore, BMSCs and ADMSCs may serve as novel treatment modalities for sepsis.
Critical Medicine Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China.
Hao
H
Ou
Critical Medicine Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China.
Shangping
S
Zhao
Critical Medicine Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China.
Yue
Y
Peng
Critical Medicine Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China.
Xuefei
X
Xiao
Critical Medicine Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China.
Qianlu
Q
Wang
Critical Medicine Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China.
Huaizeng
H
Liu
Laboratory of Shock, Department of Pathophysiology, Xiangya School of Medicine, Central South University, Changsha, Hunan 410008, P.R. China.
Xianzhong
X
Xiao
Critical Medicine Center, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, P.R. China.
Mingshi
M
Yang
D000273:Adipose Tissue / Q000166:cytology* / Q000276:immunology; D000818:Animals; D001854:Bone Marrow Cells / Q000166:cytology* / Q000276:immunology; D002469:Cell Separation; D002478:Cells, Cultured; D016130:Immunophenotyping; D007378:Interleukins / Q000097:blood / Q000276:immunology; D008070:Lipopolysaccharides / Q000276:immunology; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000276:immunology; D008807:Mice, Inbred BALB C; D018805:Sepsis / Q000097:blood / Q000276:immunology / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood / Q000276:immunology
D007378:Interleukins; D008070:Lipopolysaccharides; D014409:Tumor Necrosis Factor-alpha